A Randomized, Double-Blind (Sponsor Excepted), Placebo-Controlled Multiple Ascending Dose Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Orally Administered ARRY-403 in Patients With Type 2 Diabetes.
Phase of Trial: Phase I
Latest Information Update: 29 Aug 2012
At a glance
- Drugs ARRY 403 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- 11 Aug 2009 Results will be presented at a scientific meeting during the first half of 2010, according to an Array Biopharma media release.
- 11 Aug 2009 New trial record